The absorption and distribution of imiprothrin ([2, 5-dioxo-3-(2-propy
nyl)-1-imidazolidinyl] methyl (1R)-cis, trans-chrysanthemate) were stu
died by dosing (1R)-trans- or (1R)-cis-[imidazolidinyl-5-C-14]-imiprot
hrin orally to male and female rats at 1 (low dose) and 200 mg/kg (hig
h dose). C-14-Concentrations in blood reached maxima within 5 hr after
dosing the trans-isomer and decreased rapidly thereafter. In the rats
treated with the cis-isomer, the concentrations in blood reached a lo
wer peak within 9 hr after administration and decreased more gradually
as compared with the rats given the trans-isomer. C-14-Concentrations
in tissues decreased along with the decreases in the C-14-blood level
s in all treatment groups, these in each tissue 72 hr after administra
tion of the cis-isomer being higher than in the trans-isomer case. Met
abolites identified in the blood were 2, 4-dioxo-1-(2-propynyl)-imidaz
olidine (PGH), 5-hydroxy-2, 4-dioxo-1-(2-propynyl)-imidazolidine (PGH-
OH) and 2, 4-dioxo-imidazolidine (hydantoin, HYD) in the low dose grou
ps, whereas PGH was mainly detected in the high dose groups for both t
rans- and cis-isomers. No parent compound was observed in any dose gro
up. No marked sex-related differences appeared in the absorption and d
istribution of the trans- or cis-isomers within either dose group. The
se results suggest that imiprothrin is readily absorbed into the rat b
ody, metabolized rapidly and excreted after distribution to tissues.